$ACH News

Accendra Health Consensus Price Target Decreased by 16.53% to $1.29

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

Accendra Health Form 13G Shows Bank Of America Reports 10.8% Stake In Co. As Of Sept. 30

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

Accendra Health Names Kenneth Gardner-Smith as Next President and CEO; Expected To Assume the Role Early in Q4 of 2026, succeeding Edward Pesicka

Accendra Health Appoints Kenneth Gardner-Smith As President And CEO, Succeeding Edward Pesicka

Accendra Health (ACH) Price Target Decreased by 65.60% to 1.54

Accendra Health drops equity issuance plan as CEO succession process advances

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

Accendra Health Updates Capital Plans; Nets $45M From Non-Core Asset Sales And Sets CEO Succession Timeline For September

UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5

Citigroup Downgrades Accendra Health (ACH)

Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5

Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

Accendra Health Reports Second Quarter 2026 Financial Results

Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search

Accendra Health, Inc. 2026 Q2 - Results - Earnings Call Presentation

Accendra Health Adopts Section 382 Rights Agreement To Protect Long-Term Shareholder Value By Preserving Its Net Operating Loss Carryforwards